- Home
- CNNE vs FLGT Comparison
CNNE vs FLGT Comparison
Compare CNNE & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNNE
- FLGT
- Stock Information
- Founded
- CNNE 2014
- FLGT 2011
- Country
- CNNE United States
- FLGT United States
- Employees
- CNNE N/A
- FLGT N/A
- Industry
- CNNE Restaurants
- FLGT Medical Specialities
- Sector
- CNNE Consumer Discretionary
- FLGT Health Care
- Exchange
- CNNE Nasdaq
- FLGT Nasdaq
- Market Cap
- CNNE 869.9M
- FLGT 697.3M
- IPO Year
- CNNE N/A
- FLGT 2016
- Fundamental
- Price
- CNNE $15.26
- FLGT $28.90
- Analyst Decision
- CNNE Buy
- FLGT Buy
- Analyst Count
- CNNE 4
- FLGT 3
- Target Price
- CNNE $22.25
- FLGT $28.33
- AVG Volume (30 Days)
- CNNE 573.2K
- FLGT 332.6K
- Earning Date
- CNNE 11-10-2025
- FLGT 11-07-2025
- Dividend Yield
- CNNE 3.78%
- FLGT N/A
- EPS Growth
- CNNE N/A
- FLGT N/A
- EPS
- CNNE N/A
- FLGT N/A
- Revenue
- CNNE $430,200,000.00
- FLGT $315,549,000.00
- Revenue This Year
- CNNE N/A
- FLGT $15.19
- Revenue Next Year
- CNNE N/A
- FLGT $10.58
- P/E Ratio
- CNNE N/A
- FLGT N/A
- Revenue Growth
- CNNE N/A
- FLGT 13.61
- 52 Week Low
- CNNE $15.14
- FLGT $14.57
- 52 Week High
- CNNE $22.36
- FLGT $30.59
- Technical
- Relative Strength Index (RSI)
- CNNE 25.31
- FLGT 73.65
- Support Level
- CNNE $15.14
- FLGT $22.12
- Resistance Level
- CNNE $16.26
- FLGT $30.59
- Average True Range (ATR)
- CNNE 0.67
- FLGT 1.16
- MACD
- CNNE -0.25
- FLGT 0.65
- Stochastic Oscillator
- CNNE 8.07
- FLGT 77.96
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFC, Corporate and Other. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.